Benzinga | May 26, 2021 09:16AM EDT

AIM ImmunoTech Reports Completed Dosing Of Cohort 3 In Phase 1 Study To Assess Safety, Tolerability, Biological Activity Of Ampligen As An Intranasal Therapy

AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events.

This is consistent with results in the first two cohorts of the study and at escalating doses.The study protocol called for a total of 40 healthy subjects to receive repeated administration of either Ampligen or a placebo. Subjects in Cohort 1 received 75 ?g of Ampligen, subjects in Cohort 2 received 200 ?g of Ampligen and subjects in Cohort 3 received 500 ?g. The study is already proceeding with Cohort 4, with subjects receiving 1250 ?g.

The Centre for Human Drug Research (CHDR), an independent institute located in Leiden in the Netherlands, is conducting the Phase 1 clinical study AMP-COV-100 (CHDR2049), titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects." AIM is sponsoring and funding the clinical study.